

APAC Developed Markets Rates Strategy

Christmas carry-rolls

- Following this week's RBA rate cut and weak Q3 GDP report we still see value in front-end AUD flattening trades. We favour paying AUD 3m1y versus 3y1y given attractive entry levels and carry considerations
- Vol continues to be sold, but AUD gamma looks increasingly cheap versus vega. We suggest 6m expiries as protection against adverse US fiscal scenarios or a generally more uncertain global economic backdrop next year
- Demand for semis is likely to be robust across the curve. We expect asset swapping flows to support outperformance in long-end semis relative to swap and this is also likely to put upward pressure on the 3s10s swap EFP box.
- A buy on dips strategy in NZD rates looks appropriate given the more cautious forecasts in the latest RBNZ monetary policy statement. We expect the extension of low rate guidance to anchor interest rate expectations and as such we like receiving the belly of the 3m forward 1y-7y-10y swap butterfly as the rolldown is high.
- We do not envisage a significant probability of extraordinary policy measures from the BOJ under our base case scenario. However, a LDP-led coalition may push for bolder monetary easing than what is currently being priced in. A front-end steepening position on the JPY basis curve could best capture the impact of any aggressive injections of JPY liquidity by the BOJ.
- Life insurers' activities up to H1 12 suggest continued duration lengthening in JGB holdings. We have now closed out our short 10y JGB position.

Steven Mansell

+61-2-8225-4351
steven.mansell@citi.com

Maki Shimizu

+81-3-6270-7246
maki.shimizu@citi.com

Carl Ang

+61-2-8225-4832
carl.ang@citi.com

*With thanks to
Jacy Sun*

See Appendix A-1 for Analyst Certification, Important Disclosures and non-US research analyst disclosures.

Citi Research is a division of Citigroup Global Markets Inc. (the "Firm"), which does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Figure 1. Strategy Summary Table

APAC Developed Markets	View	Strategies
Direction	AUD rates markets remaining highly correlated to offshore, notably USTs. Markets continue to range trade, with outright duration unattractive still	Keep duration exposure very light unless ACGBs revisit the top of established trading ranges (3.4-3.5% in 10s)
Yield Curve	AUD curve is currently directional. JGB curve looks relatively anchored out to 5yrs	Hold AUD 6m1yr vs 2y1yr swap flattener. Take profits on conditional 2s10s AUD bear steepener as market has turned around within the range. 5s-10s JPY conditional steepener.
Cross-market	Cross market spread levels have opened up opportunities to position long AUD vs US trades once more	Receive AUD 5y5y vs USD. Medium-term, for positive fiscal cliff outcome sell AUD vs USD payers.
Spreads	Spreads are following risk. Swap spreads are capable of re-tightening into year end in our view, but visibility is obviously quite low currently.	Hold QTC 15s versus SAFA 15s. Keep 3s10s EFP box flattener as hedge to adverse fiscal cliff outcome.
Inflation	Neutral on AUD inflation risk currently	Look to pay fixed on 10y ZCS on any dip towards the 2.70% level
Volatility	Gamma looks to have found a base and now looks better medium-term value than vega, on selected tenors.	Keep 2m10yr vs 6m10y ATM straddles
Risk Allocation	Balanced outlook for duration unless yields rise to more attractive levels in local markets. Spread and curve trades still offer more attractive opportunities.	

Source: Citi Research

APAC Developed Markets

Australia and New Zealand Rates Strategy


Steven Mansell
+61 2 8225 4351
steven.mansell@citi.com

The front-end can run further

The RBA delivered again this week, with the 25bp rate cut bringing the total amount of easing in the current cycle to 175bp. In spite of the uninspiring accompanying RBA policy statement, which provided no forward guidance, we believe that there is still a strong argument for additional policy easing in the New Year. Our economists have concluded this following the release of surprisingly weak Q3 Australian GDP, which saw the year-on-year growth rate decelerate, from 3.8% in the previous period to 3.1%. The weakness in private consumption and private sector non-residential investment spending were both significant factors, with the former being of particular concern as slower mining investment is clearly not being adequately compensated for by household demand. For a full analysis please see: [The economic slowdown officially begins](#).

In our view, the current 48bp of additional easing that is currently priced into the OIS curve in 2013 is too moderate against what promises to be another year of challenging global economic conditions. We are currently retaining a residual receive June OIS position (with only 38bp of residual easing priced in for the first six months of next year, this still seems to be a good risk reward to us). An alternative consideration that we believe still has merit is to position front-end flattening trades on the swap curve. This has notably re-steepened as the market has moved to front-load rate cut expectations. In terms of attractive entry levels and carry characteristics we have identified the AUD 3y1y versus 3m1y spread. This spread has now re-steepened back out towards former resistance levels and should begin to retrace in a lower-for-longer policy scenario. We are electing to take profits on an existing, similar flattening position that we initiated back in July, for a modest 6.5bp profit (see Tradesheet for details).

Figure 2. OIS curve: residual easing mostly priced into H1 2013



Source: Citi Research

Figure 3. AUD 3m1y versus 3y1y spread: re-flattening potential



Source: Citi Research

Trade: Pay AUD 3m1y versus AUD 3y1y at a spread of 64bp. Target 50bp. Stop 70bp.

Below we highlight the relatively attractive carry in AUD short-end forwards, particularly in 1yr and 2yr tenors

Figure 4. 3m carry for AUD forward swap tenors (full details in the Appendix)


fwd/tenor	1Y	2Y	3Y	4Y	5Y	6Y	7Y	8Y	9Y	10Y
SPOT	- 9.9	- 0.3	2.4	3.0	3.7	4.0	3.9	3.8	3.6	3.5
3M	- 6.3	0.7	2.5	3.2	3.9	4.0	3.9	3.8	3.6	3.6
6M	- 0.4	4.0	4.3	4.7	5.2	5.0	4.8	4.5	4.2	4.3
9M	4.5	6.1	5.8	5.8	6.1	5.6	5.3	4.9	4.7	4.8
1Y	7.1	7.2	6.5	6.4	6.3	5.8	5.5	5.1	4.9	4.9
2Y	7.3	6.2	6.3	6.2	5.6	5.2	4.8	4.6	4.7	4.2
3Y	5.1	5.7	6.0	5.2	4.8	4.4	4.2	4.4	3.9	3.5
4Y	6.5	6.5	5.5	4.8	4.3	4.1	4.3	3.7	3.3	3.0
5Y	6.5	5.0	4.4	3.7	3.6	3.9	3.3	2.9	2.5	2.2

Source: Citi Research

Vols are low, but can probably go lower still

Gamma continues to be pressured lower. We see the rationale behind this with central bank policy in gradualist mode or otherwise aimed at containing tail risk via significant liquidity injections/more credible firewalls in the case of Europe. In Australia we observe that gamma has continued to be under more selling pressure than vega and this provides an opportunity to buy protection against an adverse US fiscal cliff outcome, or a more volatile global economic outlook over the course of 2013. We have previously recommended long 6m10y AUD straddles (financed by selling shorter, 2m expiry options - see *Tradesheet*). The following charts illustrate the relative richness of vega, with AUD 5y5y straddles now trading above USD equivalents and with 6m10yr now trading at similar levels to 2y10yr BP vol. We can see the case for owning parts of the gamma surface, but we are far less convinced that vega will remain supported given the global policy backdrop.

Figure 5. AUD 5y5y Vol – now higher than USD



Source: Citi Research

Figure 6. AUD 6m10yr minus 2y10yr BP Vol




Source: Citi Research

Semis – Bagging a Bargain

Carl Ang
+61 2 8225 4832
carl.ang@citi.com

We expect the more benign ratings and supply outlook for QTC to support demand for QTC as well the other semis. The positive credit rating update on Queensland has helped to clear some of the ratings risks with QTC outperforming other semis to tighten by up to 6bps in ASW terms this week following the news (see '[Stable Queensland Ratings Outlook Eases Uncertainty](#)'). Moreover, we estimate cumulative issuance to be at least AUD 6.4 billion which puts QTC on schedule with their FY 2012-13 term debt funding program of AUD 13.7 billion. Consolidation switches into the new QTC 2017 benchmark bond have also complemented existing buyback activity which has progressively moved up the curve (see Figure 7). As shown in Figure 7, for November 2012 QTC was a net buyer of its 2015 line over CY 2012. As the 2015 maturity is still relatively large with AUD 6.9 billion outstanding, we think buybacks will contribute to further short-end QTC spread compression and we still think the QTC 15-SAFA 16 yield spread can compress further (see *Tradesheet* in the rear of this publication).

Figure 7. 2012 cumulative issuance turned negative in the 2015 line



Source: Citi Research, QTC


Figure 8. QTC 15-SAFA 15 yield spread can compress to flat



Source: Citi Research


Likewise, we expect underlying demand for long-end QTC and semi spreads to remain robust particularly from domestic bank liquid asset portfolios. Although 6m term deposit spreads to bank bills have stabilized, we still think conditions remain conducive for growth in term deposits given the aggressive pricing in shorter tenors (see Figure 9). For example, 3m term deposit spreads over bank bills have widened to 100bps which is far higher than typical semi ASW spreads with a QTC constant maturity 10y ASW margin only earning +50 to +60bps. The 1m term deposit rates are also converging to bank bill yields even though their tenors are almost as short as the 30 days mandated in the Liquidity Coverage Ratio (LCR) for Basel 3. As noted in previous publications, semis are the highest yielding eligible liquid asset that banks are allowed to hold as a buffer against potential cash outflows from funding sources like term deposits. As many liquidity portfolios report on an 'available-for-sale' basis, we think long-end semi asset swaps will be targeted by banks for the relatively high carry. Credit and supply risks for semis also look contained for now as we enter the mid-year budget review season with NSW and VIC due to report on December 12 and 15 respectively. The historical richness in swaps (relative to semis) in the long-end compared to the short-end is also likely to translate into semi ASW curve flattening and 3s10s swap EFP box steepening from asset swapping flows (see Figure 10).

Figure 9. Short-tenor term deposits still aggressively priced vs BBSW



Source: Citi Research, RBA, CANSTAR

Figure 10. 3s10s swap EFP box likely to rise as semi ASW curves flatten




Source: Citi Research, Bloomberg

NZD Rates – Lord of the Flies


The decision by the RBNZ to leave the policy rate unchanged accompanied a policy assessment which embodied more hawkish language and a more medium-term focus leading the NZD 2y swap yield to gap +8bps higher (see '[Low OCR for longer](#)'). This belies the more bearish forecasts in the Monetary Policy Statement (MPS) with CPI now expected to muddle around the bottom half of the 1-3% target band over the next 2 years. Moreover, in keeping with previous MPSs the low rate guidance was extended by another quarter with the first rate hike expected around Q1 14 (see Figure 11). As we can see from Figure 11, RBNZ expectations of 3m bank bill yields have been progressively downgraded not only in terms of the level of rates but also in timing of the first rate hike. We think the more bullish language understates the immediate risks to growth which were highlighted in recent international and domestic data like the BNZ manufacturing PMI (see '[Value in Yield Convergence Trades](#)'). The NZD money market curve has flattened in line with our weaker activity indicator based on the BNZ survey with the next survey to be released on 13 December.

Figure 11. RBNZ MPS vs Market Expectations for the 3m Bank Bill Rate



Source: Citi Research, RBNZ

Figure 12. NZD 1y-1y1y Swap Spread vs 3m Fwd 1y-7y-10y Butterfly




Source: Citi Research

We see scope for the NZD short-end curve to flatten and see this as a buy-on-dips opportunity. We maintain our received position in front-end swaps like the 2y1y and also look at high roll butterflies in NZD like the 3m forward 1y-7y-10y which also offers 9bps of roll per quarter. As displayed in Figure 12, this butterfly has tracked the flattening of the money market curve as proxied by the 1y-1y1y swap spread (see Figure 12). We think this butterfly can tighten towards the bottom of its range and beyond as we consider the substance of the MPS has yet to be fully absorbed by the market. We also like this NZD curvature play for the rolldown as it is relatively high compared to G10 peers who have also maintained low rates guidance like the USD market (see Figure 13). The rolldown is also historically high versus its AUD counterpart which is almost at the bottom of its range (see Figure 14).


Trade – Receive belly of NZD 3m forward 1y-7y-10y swap butterfly. Entry +59bps. Target +49bps. Stop +64bps.

Figure 13. Cross-Section of 3m Roll on 3m Fwd 1y-7y-10y Butterfly



Source: Citi Research

Figure 14. Time Series of 3m Roll on 3m Fwd 1y-7y-10y Butterfly



Source: Citi Research


Japan Derivative Strategy

JPY Basis: A Trip Down Abe Road

With thanks to Jacy Sun


Under our base case scenario for the post election policy platform in Japan we do not envisage a significant probability of extraordinary policy measures from the BOJ, such as a reduction in the current account rate to zero or negative territory, or the establishment of a special fund to purchase foreign bonds. However, we would not rule out some form of bolder central bank intervention occurring, most likely the result of key personnel changes at the BOJ following the end of BOJ Governor Shirakawa's term in early April. Such events could cause further widening of the yen basis (i.e. deeper into negative territory), and a forward steepener on the front-end of the cross currency basis curve would be the optimal strategy if one were to position for such scenarios.

Figure 15. FX Intervention and CHF Xccy Basis (summer 2011)



Source: Citi Research, Bloomberg, IMF

Figure 16. Recent Movements of CHF Xccy Basis (Aug 2012-present)




Source: Citi Research, Bloomberg

Historically, aggressive central bank easing could exert significant downward pressure on the cross currency basis. For instance, at the height of the European sovereign-debt crisis last summer, the Swiss National Bank (SNB) engaged in substantial quantitative easing in an attempt to weaken the Swiss currency as safe haven flows flooded into the country. Major policy measures included a reduction in policy rates from 0-0.75% to 0-0.25% and an expansion of the bank sight deposits (the equivalence of BOJ current accounts) from 30 billion to 200 billion, on top of direct foreign exchange intervention in the form of spot and swap transactions. In the space of a few weeks, 3-month USD-CHF cross currency basis plunged about 150bps, from positive low 20s to negative 160bps at one point. Figure 15 compares the magnitude of movements for selected tenors of USD-CHF cross currency basis (shown as the change in price from 6 Sep 2011 levels). The first observation is that sudden flooding of CHF liquidity by the central bank affects the short-end basis most significantly, and the impact tapers off as one goes further out on the curve. We also note that the "shocks" tend to be short-lived, as the central bank exits the intervention and the massive negative basis gets arbitrated away by domestic banks that can "park" their excess reserves with the central bank at a non-negative rate. Indeed, we observed similar movements of CHF basis this week (albeit on a smaller scale) post the announcement that a major clearing bank in Switzerland will also start imposing negative interest rate on large CHF deposits (Figure 16).


Our base case scenario assumes that the outcome of this month's election produces some form of LDP-led coalition, probably with the new Komeito party, such that more expansionary monetary and fiscal policies are firmly back on the agenda until nominal growth targets are achieved (see [Japanese Elections: Political, Economic and Market Impact - A Multi-Asset Investment Perspective](#)). This in itself may push the new government to reach beyond what is currently been entertained as likely policy responses, should deflationary forces remain firmly entrenched and the global economy fail to maintain traction. Indeed, comments from BOJ's deputy governor Nishimura this week signaled a decisive stimulus bias, and signs or speculations of bold monetary easing policies could plunge the JPY basis in the run-up to the appointment of the new BOJ governors in April next year.

Figure 17. BOJ Foreign Exchange Interventions in Recent Years



Source: Citi Research, Bloomberg, MOF

Figure 18. JPY Basis Widened post BOJ FX Interventions (bps)



Source: Citi Research, Bloomberg

Based on the four FX interventions disclosed by BOJ in the past three years (Figure 17), JPY basis exhibited similar dynamics (i.e. an initial sharp drop followed by a rapid rebound) in response to a surge of JPY liquidity (Figure 18). As such, a calendar spread that pays the sub-3m forward (as dramatic policy actions are unlikely ahead of personnel changes at the BOJ) versus receiving a longer dated forward could benefit from unprecedented easing policies. However, the current rolldown profile of the front end USD-JPY cross currency basis (Figure 19) suggests that such trades are already crowded and rather costly to position. A more attractive alternative would be a forward steepener, as short tenors are more sensitive to central bank policies. For instance, one could receive 5m2m USD-JPY cross currency basis to capture the downward movement of basis versus paying 5m1y to negate the large negative carry on the receiving leg.

Figure 19. USD-JPY Fwd Xccy Basis 3-month Rolldown (bps)

	1m	2m	3m	4m	5m	6m	7m	8m	9m	10m	11m	1y	2y	3y
1m	19.0	9.3	4.4	2.7	2.1	1.1	0.0	0.0	0.3	0.1	-0.2	-0.2	-1.2	-1.3
2m	17.8	5.4	1.6	0.4	-0.7	-2.1	-2.8	-2.2	-1.8	-2.1	-2.3	-2.4	-3.4	-3.3
3m	11.7	2.1	-1.0	-2.7	-4.1	-5.1	-5.1	-4.2	-4.0	-4.2	-4.5	-4.6	-5.4	-5.0
4m	-8.0	-8.2	-7.6	-8.4	-8.7	-8.0	-6.7	-6.1	-6.0	-6.3	-6.4	-6.7	-6.2	-5.6
5m	-7.9	-7.0	-8.4	-8.7	-7.8	-6.4	-5.7	-5.6	-5.9	-6.0	-6.4	-6.8	-5.8	-5.4
6m	-6.4	-8.8	-9.0	-7.9	-6.2	-5.5	-5.4	-5.8	-5.9	-6.4	-6.8	-7.2	-5.9	-5.4
7m	-11.6	-10.6	-8.4	-6.2	-5.4	-5.2	-5.8	-6.0	-6.4	-6.8	-7.2	-7.0	-5.8	-5.2
8m	-10.5	-7.6	-4.5	-4.2	-4.2	-4.8	-5.3	-6.0	-6.4	-7.0	-6.8	-6.6	-5.6	-5.0
9m	-5.2	-2.3	-2.0	-2.9	-4.1	-4.5	-5.5	-6.2	-6.6	-6.6	-6.5	-6.2	-5.5	-5.0
10m	0.7	-0.9	-1.9	-3.6	-4.4	-5.3	-6.1	-6.7	-6.5	-6.4	-6.2	-6.0	-5.3	-4.7
11m	-2.8	-3.9	-5.1	-5.8	-6.9	-7.4	-7.9	-7.7	-7.2	-6.9	-6.8	-6.6	-5.6	-4.8
1y	-6.1	-6.8	-7.0	-8.3	-8.5	-8.7	-8.5	-8.0	-7.4	-7.3	-6.9	-6.7	-5.5	-4.7


Source: Citi Research

JGB Rates Strategy

Maki Shimizu
+81-3-6270-7246
maki.shimizu@citi.com


Around this time of year we can usually gauge next fiscal year's JGB issuance schedule. However, this year with the General Election to be held on December 16 there has been a delay in compilation of the main government budget for FY2013. Such uncertainties as well as continued downward bias in bond yields seem to be forcing investors to face more challenging environment than usual, and we expect the JGB market over the January-March period into next fiscal year to become more volatile in contrast to the market as it is now. After the 10yr JGB yield broke the 0.7% level and reached its lowest level in 9 years, the market is reminded of the historic low (0.43%) established in June 2003 (Figure 20). Many domestic investors seem to have expected higher yields for FY2012 based on Spring bond investment strategy plans, and in the scenario that bond yields maintain current levels or head lower investors may need to lighten their exposures to JGBs and shift focus to other assets for better returns in anticipation of March book closing. As in the past two years, high-coupon old 5yr bonds will be redeemed next year which is likely to detract from investment returns. Meanwhile, as bond yields get closer to zero, the upside room for capital gains shrink. Extending the bond maturity in the portfolio would be one way of securing returns, yet investors' risk appetite may have contracted, resulting in a continued decline in volatility. The aggregate JGB issuance into the market is far larger than FY2003, in which the proportion of the super-long JGBs is more than threefold today (Figure 21). The abrupt jump in yields following the VaR shock (Phase 3 in Figure 20) may lead investors to hesitate buying long-tenor bonds and they could possibly revise the proportion of JGB holdings.

Figure 20. JGB Yields During Old QE [%]



Source: Bloomberg, Citi Research

Figure 21. JGB Issuance by Maturity During Old QE




Source: MoF, Citi Research

Lifers' latest activities

The 1H FY2012 results reports of major life insurers through last week show that they have lengthened the maturities of their bond portfolios in preparation for the tightening of solvency rules and the introduction of mark-to-market accounting for liabilities. The holdings of marketable securities by the biggest nine Japanese life insurers grew by ¥1.7trn over six months to ¥120.4trn at end-September. JGBs had the highest weighting, at 48.9% of total assets, having grown from 47.7%, or ¥2.3trn, since end-FY2011. The main changes in holdings of other assets were a ¥1.7trn decrease in Japanese equities and a ¥1.3trn increase in foreign bonds. So to adapt to new solvency rules, life insurers reduced holdings of equities, which are


subject to greater price volatility risk, and directed inflows of new funds into JGBs and foreign bonds.

Figure 22. Composition of Securities Holding[¥trn]



Source: Citi Research based on Lifers Financial Report


Figure 23. Equity Trading Flows by Lifers [¥trn]



Source: BoJ, Citi Research


Life insurers' investment stances have changed relative to last fiscal year. In FY2011, the ¥8.9trn increase in holdings of JGBs exceeded the ¥7.9trn growth in holdings of marketable securities overall. The holdings of foreign bonds increased by only ¥0.3trn. With a little more than half of this fiscal year having passed, the rate of growth in JGB holdings has slowed markedly, as life insurers have switched some of the funds they had intended to invest in JGBs to foreign bonds (Figure 24), because JGB yields have fallen short of expectations.

Figure 24. Net Foreign Bond Purchases by Lifers [¥trn]



Source: MoF, Citi Research

Figure 25. JGB Holding by Maturity [¥trn]




Source: Citi Research based on Lifers Financial Report

Life insurers have also lengthened the maturity of their JGB portfolios. Figure 25 shows total JGB holdings by the nine big life insurers by period to maturity. The weighting of JGBs with 10 years or longer to maturity increased from 75.6% at end-March to 76.3% at end-September. There was little change in holdings of other maturities, so the ¥2.2trn growth in this sector accounts for almost all the increase in

overall JGB holdings. Last fiscal year, however, holdings JGBs grew by ¥8.9trn, with those of maturities longer than 10 years increasing by ¥8.4trn and those of 7-10 years increasing ¥1.3trn. In contrast, holdings of JGBs declined by ¥0.6trn in both zones with maturities of less than one year and 5-7 years, so reshuffling of portfolios to lengthen maturities affected all zones. If current interest rates continue to prevail during 2H FY2012, the pace of super-long JGB buying by life insurers may not increase (Figure 26). The yield curve is unlikely to continue to bull flatten.

If, for example, the yield on 20yr and 30yr JGBs rose by 10-20bp, life insurers could probably look to switch from medium- and long-term JGBs to super-long JGBs, causing the yield curve to bear flatten. We expect a bear market after the December 16 election, and the 7-10yr zone to underperform. We also think that futures selling by foreign players and profit taking by banks in the long-term sector will grow. In such case, the shape of the butterfly spread will be corrected from what looks like an extreme level (Figure 27).

Figure 26. Yen Bond Investment by Domestic Lifers and Non-Lifers[¥trn]



Source: JSDA, Citi Research

Figure 27. JGB5x10x20yr Fly [bp]



Source: Citi Research

Strategy: Closed short 10yr JGB position

We closed an outright short 10yr JGB trade at our stop out limit. Current 10yr JGB yield declined to 0.695% on Nov 30 to renew its lowest since June 2003. Although the trend of equity's advance and yen depreciation followed the Diet dissolution as expected, the US Treasury bond market remained solid and strong expectations for the BoJ's aggressive easing encouraged bullish investors. Despite the fact that many investors have an outlook of higher JGB yields going forward, the timing is expected to be pushed back to after the election. So, even only in short-term dealings, investors did not retreat from buying a long-term sector. We retain our conditional steepener of 5x10yr swaps on back of a paradigm shift of policy focus from fiscal reconstruction to growth strategies in 2H FY2012. The key uncertainty near term is USD/JPY, in our view. Any progress in the talks of US fiscal cliff or European debt issues may bring USD higher and the trends of equity rally and yen depreciation may continue as Citi expects into 1Q 2013. Under such circumstances, we expect 7-10yr tenors of JGB, where richness has not retreated on the curve, to be under pressure for profit taking.

Tradesheet

New Trades: Receive belly of NZD 3m forward 1y-7y-10y swap butterfly. Entry +59bps. Target +49bps. Stop +64bps.

Pay AUD 3m1y versus AUD 3y1y at a spreads of 64bp. Target 50bp. Stop 70bp.

Closed Trades: Pay AUD 6m1y vs 2y1y for a profit of 6.5bp

Figure 28. Record of Open Trades

Country	Trade	Levels	Publication Date	
AUD	Buy AUD 1y2y 75bp wide 1/2/1 receiver fly	Open 22c Current 52.81c P&L 30.81c Target 115c Stop 0c	APAC DMRS 29 March 2012	
AUD	Buy ACGB 5.5% April 2023. Sell ACGB 4.5% April 2020	Open 29.5bp Current 23bp P&L 6.5bp Target 20bp Stop 35bp	APAC DMRS 8 May 2012	
AUD	Sell AUD 5y5y ATM Straddle	Open 580c Current 573.53c P&L 6.47c Target 520c Stop 620c	APAC DMRS 21 June 2012	
AUD	Buy ACGB 4.75% April 2027, Sell ACGB 4.25% July 2017	Open 79bp Current 76.5bp P&L 2.5bp Target 60bp Stop 90bp	APAC DMRS 19 July 2012	
JPY	JPY 6m fwd 5y/10y ATM conditional steepener via payers	Open 46c Current 12.31c P&L -33.69c Target 150c Stop 0c	APAC DMRS 13 September 2012	
AUD	Buy QTC 15, Sell SAFA 15	Open 10bp Current 3.5bp P&L 6.5bp Target 0bp Stop 15bp	APAC DMRS 13 September 2012	
AUD	Sell AUD 3m3y 50bp wide strangle and buy 1y3y 50bp OTM receiver	Open 0bp Current 32.69c P&L 32.69c Target 180c Stop -85c	APAC DMRS 27 September 2012	
NZD	Receive NZD 2y1y	Open 300bp Current 300.49bp P&L -0.49bp Target 2.60% Stop 3.20%	APAC DMRS 4 October 2012	
AUD	Sell AUD 3m10y 75bp OTM payer and buy 55bp OTM receiver	Open 12c Current -0.48c P&L -12.48c Target 200c Stop -150c	APAC DMRS 4 October 2012	
AUD	Sell AUD 2m10y ATM straddles vs 6m10y	Open 160c Current 199.59c P&L 39.59c Target 240c Stop 120c	APAC DMRS 1 November 2012	

Source: Citi Research

Figure 29. Record of Open Trades

AUD	AUD 3s10s EFP box flattener		Open	22bp		
			Current	27.75bp		
<i>Spreads</i>	Pay AUD 3s EFP		P&L -5.75bp		APAC DMRS 1 November 2012	
	Receive AUD 10s EFP		Target	10bp		
			Stop	30bp		
AUD/USD	Sell 1.11 x AUD 6m10y 4% payer and buy 1 x USD 6m10y ATM payer		Open	0c		
			Current	-3.11c		
<i>Cross-market</i>	Sell 1.11 x AUD 6m10y 4% payer		P&L -3.11c		APAC DMRS 22 November 2012	
	Buy 1 x USD 6m10y ATM payer		Target	210c		
			Stop	-70c		
AUD/USD	Receive AUD 5y5y versus USD 5y5y		Open	177bp		
			Current	168.83bp		
<i>Cross-market</i>	Receive AUD5y5y		P&L 8.17bp		APAC DMRS 28 November 2012	
	Pay USD 5y5y		Target	140bp		
			Stop	200bp		
AUD	AUD Dec12 / Jun13 OIS Flattener		Open	-34.5bp		
			Current	-40.8bp		
<i>Swap Curve</i>	Pay AUD Dec12 OIS		P&L 6.3bp		APAC DMRS 30 November 2012	
	Receive AUD Jun13 OIS		Target	-60bp		
			Stop	-22bp		

Source: Citi Research

Appendix

Figure 30. Australia relative value by sector

Versus Fitted Yield Curve							Versus Swap Curve (CAS)						
	Rank		ZScore		Issued	Size (bn)		Rank		ZScore		Issued	Size (bn)
ACGB	Richest	1	AUT 4.75 Jun16	-2.14	Jun10	11.0	Richest	1	AUT 3.25 Apr29	-0.71	Oct12	3.3	
		2	AUT 4.75 Oct15	-1.75	Apr11	2.2		2	AUT 2.75 Apr24	0.69	Apr12	0.0	
		3	AUT 3.25 Apr29	-1.47	Oct12	3.3		3	AUT 4.75 Apr27	0.84	Oct11	3.3	
		4	AUT 4.50 Oct14	-1.24	Apr10	9.2		4	AUT 5.50 Apr23	0.87	Apr11	3.2	
		5	AUT 5.75 May21	-1.13	May07	12.8		5	AUT 5.75 Jul22	0.97	Jan10	7.4	
	Cheapest	5	AUT 2.75 Apr24	0.50	Apr12	0.0	Cheapest	5	AUT 4.75 Jun16	1.16	Jun10	11.0	
		4	AUT 5.50 Dec13	0.61	Dec09	9.3		4	AUT 4.50 Oct14	1.19	Apr10	9.2	
		3	AUT 6.50 May13	1.54	May00	16.7		3	AUT 4.75 Oct15	1.22	Apr11	2.2	
		2	AUT 5.50 Jan18	1.62	Jul10	8.3		2	AUT 6.25 Apr15	1.42	Apr02	14.1	
		1	AUT 6.25 Apr15	1.86	Apr02	14.1		1	AUT 6.50 May13	1.62	May00	16.7	
NSW	Richest	1	NSW 6.00 Apr16	-1.25	Oct09	1.0	Richest	1	NSW 6.00 Feb18	0.28	Feb11	4.3	
		2	NSW 6.00 Apr15	-1.19	Apr11	2.0		2	NSW 4.00 Feb17	0.32	Feb12	1.0	
		3	NSW 4.00 Feb17	-1.07	Feb12	1.0		3	NSW 6.00 May20	0.42	Nov09	4.5	
		4	NSW 2.75 Jul14	-0.96	Jul12	0.5		4	NSW 6.00 Mar22	0.46	Sep11	0.6	
		5	NSW 6.00 May20	-0.96	Nov09	4.5		5	NSW 6.00 Apr16	0.63	Oct09	1.0	
	Cheapest	5	NSW 6.00 May30	-0.75	May10	0.2	Cheapest	5	NSW 6.00 Apr15	1.35	Apr11	2.0	
		4	NSW 6.00 Apr19	-0.74	Apr08	3.5		4	NSW 5.50 Aug13	1.39	Feb10	5.0	
		3	NSW 6.00 May23	-0.67	May07	2.6		3	NSW 6.00 Jun20	1.41	Jun09	1.1	
		2	NSW 5.00 Aug24	-0.33	Feb12	0.9		2	NSW 6.00 Apr19	1.62	Apr08	3.5	
		1	NSW 5.25 May13	-0.18	May09	0.6		1	NSW 5.25 May13	1.73	May09	0.6	
QTC	Richest	1	QTC 6.00 Oct15	-1.43	Oct10	6.9	Richest	1	QTC 6.00 Oct15	-1.21	Oct10	6.9	
		2	QTC 6.00 Apr16	-1.31	Apr10	5.1		2	QTC 6.00 Feb18	-1.13	Feb11	4.4	
		3	QTC 6.50 Mar33	-1.29	Mar08	0.7		3	QTC 6.50 Mar33	-1.12	Mar08	0.7	
		4	QTC 5.75 Nov14	-1.25	Nov09	7.8		4	QTC 6.00 Apr16	-0.97	Apr10	5.1	
		5	QTC 6.25 Feb20	-1.14	Feb10	5.9		5	QTC 6.25 Feb20	-0.93	Feb10	5.9	
	Cheapest	5	QTC 6.00 Aug13	-1.09	Feb02	3.3	Cheapest	5	QTC 6.00 Jul22	-0.58	Jan11	3.8	
		4	QTC 5.50 Jun21	-1.02	Jun11	1.5		4	QTC 5.75 Jul24	-0.48	Jan11	1.1	
		3	QTC 6.00 Jul22	-0.87	Jan11	3.8		3	QTC 5.75 Nov14	-0.44	Nov09	7.8	
		2	QTC 6.00 Aug13	-0.79	Aug10	3.5		2	QTC 6.00 Aug13	0.69	Feb02	3.3	
		1	QTC 5.75 Jul24	-0.70	Jan11	1.1		1	QTC 6.00 Aug13	0.75	Aug10	3.5	
TCV	Richest	1	TCV 5.75 Nov16	-1.14	Nov04	3.5	Richest	1	TCV 6.00 Jun20	-0.16	Jun09	3.4	
		2	TCV 6.00 Jun20	-1.10	Jun09	3.4		2	TCV 5.50 Nov18	0.00	Nov08	3.0	
		3	TCV 5.50 Nov18	-1.06	Nov08	3.0		3	TCV 6.00 Oct22	0.33	Oct03	3.1	
		4	TCV 4.75 Oct14	-1.06	Apr03	4.0		4	TCV 5.50 Nov26	0.40	May11	0.6	
	Cheapest	4	TCV 6.00 Oct22	-0.71	Oct03	3.1	Cheapest	4	TCV 5.75 Nov16	0.47	Nov04	3.5	
		3	TCV 5.50 Nov26	-0.58	May11	0.6		3	TCV 5.50 Dec24	0.47	Jun10	2.3	
		2	TCV 5.50 Dec24	-0.47	Jun10	2.3		2	TCV 6.50 Mar33	0.62	Sep10	0.1	
		1	TCV 6.50 Mar33	0.00	Sep10	0.1		1	TCV 4.75 Oct14	0.74	Apr03	4.0	
	WATC	Richest	1	WATC 7.00 Apr15	-1.27	Oct06	2.6	Richest	1	WATC 6.00 Oct23	0.40	Mar05	0.2
2			WATC 8.00 Jul17	-1.04	Jan01	2.5	2		WATC 8.00 Jul17	0.52	Jan01	2.5	
3			WATC 5.50 Apr14	-1.04	Apr10	1.9	3		WATC 7.00 Jul21	0.75	Jul02	0.8	
Cheapest		3	WATC 7.00 Oct19	-0.95	Apr01	1.8	Cheapest	3	WATC 7.00 Oct19	0.93	Apr01	1.8	
		2	WATC 7.00 Jul21	-0.87	Jul02	0.8		2	WATC 5.50 Apr14	1.00	Apr10	1.9	
		1	WATC 6.00 Oct23	-0.59	Mar05	0.2		1	WATC 7.00 Apr15	1.24	Oct06	2.6	

ZScore calculated using 6M history
2y,5y,7y,10y,20y,30y denote the OTR bonds
Analytics as of 5-Dec-12

Source: Citi Research

Figure 31. Australia relative value by sector

		Versus Fitted Yield Curve					Versus Swap Curve (CAS)				
		Rank		ZScore	Issued	Size (bn)	Rank		ZScore	Issued	Size (bn)
SAFA	Richest	1	SAFA 5.75 Sep17	-1.30	Mar10	2.0	1	SAFA 5.75 Sep17	-1.21	Mar10	2.0
		2	SAFA 5.75 Apr15	-1.21	Apr09	2.0	2	SAFA 5.00 May21	-1.07	May11	1.0
	Cheapest	2	SAFA 5.25 Jun14	-0.99	Dec10	2.0	2	SAFA 5.25 Jun14	0.31	Dec10	2.0
		1	SAFA 6.00 May13	-0.32	Nov06	2.2	1	SAFA 6.00 May13	1.16	Nov06	2.2
NTER	Richest	1	NTER 6.25 Oct15	-1.37	Apr10	0.5	1	NTER 6.25 Oct15	-0.98	Apr10	0.5
	Cheapest			-6.00					-10.00		
		1	NTER 5.75 Jul14	-1.24	Jul09	0.5	1	NTER 5.75 Jul14	-0.67	Jul09	0.5
TASM	Richest	1	TASM 6.00 Jun20	-1.31	Jun09	0.1	1	TASM 6.50 May13	-1.51	Nov06	0.8
		2	TASM 5.00 Sep17	-1.09	Sep11	0.5	2	TASM 6.00 Jun20	-0.85	Jun09	0.1
	Cheapest	2	TASM 6.50 May13	0.00	Nov06	0.8	2	TASM 6.50 Apr15	0.06	Oct06	0.5
		1	TASM 6.50 Apr15	0.00	Oct06	0.5	1	TASM 5.50 Jun14	0.53	Jun10	0.8

ZScore calculated using 6M history
2y,5y,7y,10y,20y,30y denote the OTR bonds
Analytics as of 5-Dec-12

Source: Citi Research

Figure 32. Australia relative value by maturity

		Versus Fitted Yield Curve					Versus Swap Curve (CAS)				
		Rank		ZScore	Issued	Size (bn)	Rank		ZScore	Issued	Size (bn)
AUS 1-3	Richest	1	AUT 4.75 Oct15	-1.75	Apr11	2.2	1	QTC 6.00 Oct15	-1.21	Oct10	6.9
		2	QTCX 6.00 Oct15	-1.71	Apr03	0.6	2	NTER 6.25 Oct15	-0.98	Apr10	0.5
		3	QTC 6.00 Oct15	-1.43	Oct10	6.9	3	NTER 5.75 Jul14	-0.67	Jul09	0.5
		4	NTER 6.25 Oct15	-1.37	Apr10	0.5	4	QTC 5.75 Nov14	-0.44	Nov09	7.8
		5	WATC 7.00 Apr15	-1.27	Oct06	2.6	5	SAFA 5.75 Apr15	-0.23	Apr09	2.0
	Cheapest	5	NSW 2.75 Jul14	-0.96	Jul12	0.5	5	WATC 7.00 Apr15	1.24	Oct06	2.6
		4	AUT 6.25 Jun14	-0.57	Jun08	11.9	4	NSWX 5.50 Aug14	1.25	Aug03	1.0
		3	TASM 6.50 Apr15	0.00	Oct06	0.5	3	NSW 2.75 Jul14	1.27	Jul12	0.5
		2	AUT 5.50 Dec13	0.61	Dec09	9.3	2	NSW 6.00 Apr15	1.35	Apr11	2.0
		1	AUT 6.25 Apr15	1.86	Apr12	14.1	1	AUT 6.25 Apr15	1.42	Apr12	14.1
AUS 4-7	Richest	1	ACT 5.50 Jun18	-1.33	Jun11	0.3	1	ACT 5.50 Jun18	-1.31	Jun11	0.3
		2	SAFA 5.75 Sep17	-1.30	Mar10	2.0	2	SAFA 5.75 Sep17	-1.21	Mar10	2.0
		3	QTC 6.00 Feb18	-1.14	Feb11	4.4	3	QTC 6.00 Feb18	-1.13	Feb11	4.4
		4	TASM 5.00 Sep17	-1.09	Sep11	0.5	4	TASM 5.00 Sep17	-0.34	Sep11	0.5
		5	NSW 4.00 Feb17	-1.07	Feb12	1.0	5	TCV 5.50 Nov18	0.00	Nov08	3.0
	Cheapest	5	NSW 6.00 Apr19	-0.74	Apr08	3.5	5	AUT 5.50 Jan18	1.10	Jul10	8.3
		4	AUT 4.25 Jul17 (5y)	-0.07	Jul11	0.0	4	AUT 6.00 Feb17	1.15	Feb04	14.5
		3	AUT 5.25 Mar19	0.44	Sep05	13.9	3	NSW 5.50 Mar17	1.33	Mar06	3.3
		2	AUT 6.00 Feb17	0.46	Feb04	14.5	2	NSWX 5.50 Mar17	1.38	Mar06	1.6
		1	AUT 5.50 Jan18	1.62	Jul10	8.3	1	NSW 6.00 Apr19	1.62	Apr08	3.5
AUS 8-10	Richest	1	SAFA 5.00 May21	-1.19	May11	1.0	1	SAFA 5.00 May21	-1.07	May11	1.0
		2	AUT 5.75 May21	-1.13	May07	12.8	2	QTC 5.50 Jun21	-0.77	Jun11	1.5
		3	QTC 5.50 Jun21	-1.02	Jun11	1.5	3	QTC 6.00 Jul22	-0.58	Jan11	3.8
		4	WATC 7.00 Jul21	-0.87	Jul02	0.8	4	TCV 6.00 Oct22	0.33	Oct03	3.1
	Cheapest	4	QTC 6.00 Jul22	-0.87	Jan11	3.8	4	NSW 6.00 Mar22	0.46	Sep11	0.6
		3	NSW 6.00 Mar22	-0.77	Sep11	0.6	3	WATC 7.00 Jul21	0.75	Jul02	0.8
		2	TCV 6.00 Oct22	-0.71	Oct03	3.1	2	AUT 5.75 Jul22	0.97	Jan10	7.4
		1	AUT 5.75 Jul22	0.08	Jan10	7.4	1	AUT 5.75 May21	1.03	May07	12.8
					#N/A					#N/A	
AUS >10	Richest	1	AUT 3.25 Apr29	-1.47	Oct12	3.3	1	QTC 6.50 Mar33	-1.12	Mar08	0.7
		2	QTC 6.50 Mar33	-1.29	Mar08	0.7	2	AUT 3.25 Apr29	-0.71	Oct12	3.3
		3	AUT 4.75 Apr27	-0.76	Oct11	3.3	3	QTC 5.75 Jul24	-0.48	Jan11	1.1
		4	NSW 6.00 May30	-0.75	May10	0.2	4	TCV 5.50 Nov26	0.40	May11	0.6
		5	QTC 5.75 Jul24	-0.70	Jan11	1.1	5	WATC 6.00 Oct23	0.40	Mar05	0.2
	Cheapest	5	TCV 5.50 Dec24	-0.47	Jun10	2.3	5	NSW 6.00 May30	0.70	May10	0.2
		4	NSW 5.00 Aug24	-0.33	Feb12	0.9	4	NSW 6.00 May23	0.72	May07	2.6
		3	TCV 6.50 Mar33	0.00	Sep10	0.1	3	AUT 4.75 Apr27	0.84	Oct11	3.3
		2	AUT 5.50 Apr23 (10y)	0.02	Apr11	3.2	2	AUT 5.50 Apr23 (10y)	0.87	Apr11	3.2
		1	AUT 2.75 Apr24	0.50	Apr12	0.0	1	NSW 5.00 Aug24	0.89	Feb12	0.9

ZScore calculated using 6M history
2y,5y,7y,10y,20y,30y denote the OTR bonds
Analytics as of 5-Dec-12


Source: Citi Research

Figure 33. 3M carry in AUD swaps¹

fwd/tenor	1Y	2Y	3Y	4Y	5Y	6Y	7Y	8Y	9Y	10Y	12Y	15Y	20Y	25Y	30Y
SPOT	- 9.9	- 0.3	2.4	3.0	3.7	4.0	3.9	3.8	3.6	3.5	3.4	2.7	1.8	1.1	0.8
3M	- 6.3	0.7	2.5	3.2	3.9	4.0	3.9	3.8	3.6	3.6	3.3	2.7	1.8	1.1	0.8
6M	- 0.4	4.0	4.3	4.7	5.2	5.0	4.8	4.5	4.2	4.3	3.8	3.1	2.0	1.4	1.0
9M	4.5	6.1	5.8	5.8	6.1	5.6	5.3	4.9	4.7	4.8	4.1	3.4	2.2	1.5	1.2
1Y	7.1	7.2	6.5	6.4	6.3	5.8	5.5	5.1	4.9	4.9	4.1	3.5	2.2	1.6	1.2
2Y	7.3	6.2	6.3	6.2	5.6	5.2	4.8	4.6	4.7	4.2	3.6	3.0	1.7	1.1	0.8
3Y	5.1	5.7	6.0	5.2	4.8	4.4	4.2	4.4	3.9	3.5	2.9	2.4	1.1	0.7	0.4
4Y	6.5	6.5	5.5	4.8	4.3	4.1	4.3	3.7	3.3	3.0	2.6	1.9	0.7	0.4	0.1
5Y	6.5	5.0	4.4	3.7	3.6	3.9	3.3	2.9	2.5	2.2	2.0	1.1	0.2	- 0.1	- 0.3
6Y	3.5	3.3	3.0	2.8	3.4	2.7	2.3	2.0	1.7	1.7	1.3	0.3	- 0.3	- 0.6	- 0.7
7Y	3.2	2.7	2.8	3.4	2.6	2.1	1.8	1.5	1.5	1.3	0.7	- 0.2	- 0.7	- 0.9	- 0.9
8Y	2.2	2.6	3.7	2.5	1.9	1.5	1.2	1.2	1.1	0.8	0.0	- 0.7	- 1.0	- 1.2	- 1.2
9Y	3.0	4.5	2.9	1.8	1.4	1.0	1.1	0.9	0.6	0.2	- 0.6	- 1.0	- 1.3	- 1.4	- 1.3
10Y	6.0	2.8	1.7	1.0	0.6	0.7	0.6	0.3	- 0.1	- 0.6	- 1.2	- 1.4	- 1.6	- 1.7	- 1.5

Source: Citi Research

Figure 34. 3M carry profile of ACGB²



Source: Citi Research

Figure 35. 3M carry table of ACGB

ACGB	Carry	Rolldown	Total
1y	-5.1	-6.5	-11.6
2y	-3.8	-1.4	-5.2
3y	-2.6	0.0	-2.6
4y	-1.9	0.9	-1.0
5y	-1.2	1.9	0.8
6y	-0.5	2.4	1.8
7y	-0.2	1.9	1.8
8y	0.1	1.9	2.0
9y	0.3	1.8	2.2
10y	0.5	2.0	2.5
11y	0.7	2.3	3.1
12y	0.9	2.3	3.2
13y	1.0	1.9	3.0
14y	1.1	1.7	2.8
15y	1.2	1.6	2.8

Source: Citi Research

¹ Sectors with carry more than 5bp is highlighted in green while the carry less than 5bp is highlighted in red.

² ACGB carry profile and table is calculated from the relative value curve and it may vary from individual bonds given the repo rate.

Figure 36. 3M carry in NZD swaps³

fwd/tenor	1Y	2Y	3Y	4Y	5Y	6Y	7Y	8Y	9Y	10Y	12Y	15Y	20Y
SPOT	- 3.1	2.5	4.6	5.6	6.3	6.8	6.6	6.3	5.7	5.1	3.7	3.1	2.7
3M	- 0.7	3.3	4.9	5.7	6.6	6.7	6.6	6.1	5.6	4.8	3.5	3.1	2.7
6M	4.0	5.7	6.6	7.0	7.9	7.6	7.3	6.7	6.1	5.2	3.9	3.4	3.0
9M	6.6	7.5	7.9	8.2	8.8	8.3	7.9	7.1	6.4	5.4	4.1	3.7	3.2
1Y	6.8	7.7	7.9	8.3	8.5	8.1	7.5	6.8	6.0	5.0	3.9	3.5	3.0
2Y	8.6	8.5	8.8	9.0	8.4	7.7	6.8	5.9	4.8	4.1	3.4	3.1	2.6
3Y	8.4	8.9	9.2	8.3	7.5	6.5	5.5	4.3	3.5	3.0	2.8	2.6	2.1
4Y	9.4	9.6	8.3	7.3	6.1	5.0	3.7	2.8	2.3	2.2	2.1	2.0	1.6
5Y	9.9	7.8	6.6	5.2	4.0	2.6	1.7	1.3	1.2	1.2	1.3	1.2	1.0
6Y	5.7	4.9	3.6	2.4	0.9	0.1	- 0.2	- 0.1	0.0	0.2	0.4	0.3	0.3
7Y	4.0	2.4	1.2	- 0.4	- 1.2	- 1.3	- 1.1	- 0.8	- 0.6	- 0.4	- 0.2	- 0.2	- 0.2
8Y	0.7	- 0.3	- 2.0	- 2.7	- 2.5	- 2.1	- 1.7	- 1.3	- 1.0	- 0.8	- 0.7	- 0.6	- 0.5
9Y	- 1.5	- 3.4	- 3.9	- 3.4	- 2.7	- 2.1	- 1.6	- 1.3	- 1.0	- 0.9	- 0.8	- 0.7	- 0.6
10Y	- 5.5	- 5.2	- 4.1	- 3.1	- 2.3	- 1.6	- 1.2	- 1.0	- 0.8	- 0.8	- 0.7	- 0.6	- 0.5

Source: Citi Research

³ Sectors with carry more than 5bp is highlighted in green while the carry less than 5bp is highlighted in red.

Figure 37. Japan relative value by maturity

Versus Fitted Yield Curve						Versus Swap Curve (YYS)					
JGB 2-7	Richest ↑ ↓ Cheapest	Rank	Issue	Size (¥1n)	ZScore	Richest ↑ ↓ Cheapest	Rank	Issue	Size (¥1n)	ZScore	
		1	#294 1.70 Jun18	2.10	-1.88		Jul08	1	#302 1.40 Jun19	2.25	1.02
		2	#276 1.60 Dec15	3.13	-0.95	Feb06	2	#301 1.50 Jun19	4.31	1.04	
		3	#265 1.50 Dec14	3.28	-0.95	Dec04	3	#303 1.40 Sep19	4.65	1.05	
		4	#266 1.40 Dec14	3.29	-0.95	Jan05	4	#304 1.30 Sep19	2.39	1.06	
		5	#274 1.50 Dec15	3.38	-0.95	Dec05	5	#294 1.70 Jun18	2.10	1.18	
		5	#106 0.20 Sep17 (5y)	2.64	1.99	Sep12	5	#104 0.20 Mar17	2.50	1.98	
		4	#299 1.30 Mar19	3.87	2.20	Mar09	4	#101 0.40 Dec16	2.85	1.99	
		3	#297 1.40 Dec18	2.11	2.32	Dec08	3	#284 1.70 Dec16	9.44	2.00	
		2	#298 1.30 Dec18 (7y)	4.00	2.49	Jan09	2	#102 0.30 Dec16	5.42	2.00	
		1	#300 1.50 Mar19	2.28	2.50	May09	1	#323 0.10 Dec14	2.70	2.03	
		1	#308 1.30 Jun20	2.25	-1.77	Jun10	1	#55 2.00 Mar22	0.99	-2.64	
		2	#55 2.00 Mar22	0.99	-1.70	Apr02	2	#53 2.10 Dec21	0.85	-2.39	
		3	#53 2.10 Dec21	0.85	-1.28	Dec01	3	#324 0.80 Jun22	2.63	-2.32	
		4	#310 1.00 Sep20	4.74	-1.26	Sep10	4	#323 0.90 Jun22	2.30	-2.28	
		5	#309 1.10 Jun20	4.76	-1.21	Jul10	5	#54 2.20 Dec21	0.90	-2.16	
		5	#317 1.10 Sep21	2.31	2.18	Sep11	5	#307 1.30 Mar20	2.57	0.71	
		4	#57 1.90 Jun22	0.97	2.38	Aug02	4	#47 2.20 Sep20	0.69	0.90	
		3	#322 0.90 Mar22	2.53	2.51	May12	3	#45 2.40 Mar20	0.87	1.04	
		2	#305 1.30 Dec19 (JB)	7.14	2.65	Dec09	2	#46 2.20 Jun20	0.70	1.11	
		1	#46 2.20 Jun20	0.70	3.34	Apr00	1	#305 1.30 Dec19 (JB)	7.14	1.20	
		1	#93 2.00 Mar27	1.15	-2.17	Mar07	1	#93 2.00 Mar27	1.15	-2.80	
		2	#77 2.00 Mar25	0.81	-2.00	May05	2	#94 2.10 Mar27	1.83	-2.67	
		3	#73 2.00 Dec24	1.36	-1.99	Dec04	3	#83 2.10 Dec25	0.95	-2.63	
		4	#98 2.10 Sep27	1.04	-1.94	Nov07	4	#82 2.10 Sep25	1.53	-2.59	
		5	#75 2.10 Mar25	0.73	-1.90	Mar05	5	#81 2.00 Sep25	0.88	-2.59	
		5	#87 2.20 Mar26	0.96	1.19	May06	5	#68 2.20 Mar24	0.68	-1.76	
		4	#70 2.40 Jun24	1.44	1.25	Jun04	4	#61 1.00 Mar23	1.21	-1.45	
		3	#60 1.40 Dec22	1.12	1.52	Feb03	3	#60 1.40 Dec22	1.12	-1.41	
		2	#68 2.20 Mar24	0.68	1.61	Apr04	2	#59 1.70 Dec22	1.07	-1.33	
		1	#61 1.00 Mar23	1.21	1.65	Apr03	1	#326 0.70 Dec22	2.30	1.00	
		1	#102 2.40 Jun28	1.04	-2.63	Jun08	1	#102 2.40 Jun28	1.04	-2.75	
		2	#107 2.10 Dec28	1.04	-2.26	Dec08	2	#103 2.30 Jun28	0.91	-2.62	
		3	#100 2.20 Mar28	1.84	-2.17	Mar08	3	#100 2.20 Mar28	1.84	-2.62	
		4	#106 2.20 Sep28	0.94	-2.12	Oct08	4	#107 2.10 Dec28	1.04	-2.61	
		5	#105 2.10 Sep28	1.90	-1.84	Sep08	5	#105 2.10 Sep28	1.90	-2.59	
		5	#129 1.80 Jun31	1.27	1.07	Aug11	5	#126 2.00 Mar31	1.15	-1.08	
		4	#127 1.90 Mar31	1.11	1.09	May11	4	#131 1.70 Sep31	1.10	-1.07	
		3	#137 1.70 Jun32	1.27	1.22	Jun12	3	#128 1.90 Jun31	2.23	-1.06	
		2	#140 1.70 Sep32 (20y)	1.25	1.36	Sep12	2	#137 1.70 Jun32	1.27	-0.97	
		1	#139 1.60 Jun32	1.20	1.58	Aug12	1	#138 1.50 Jun32	1.37	-0.97	
		1	#13 2.00 Dec33	0.72	-1.83	Feb04	1	#31 2.20 Sep39	2.21	-2.85	
		2	#12 2.10 Sep33	0.52	-1.60	Nov03	2	#35 2.00 Sep41	3.01	-2.83	
		3	#19 2.30 Jun35	0.72	-1.46	Jul05	3	#34 2.20 Mar41	2.77	-2.83	
		4	#22 2.50 Mar36	0.77	-1.33	Apr06	4	#30 2.30 Mar39	2.27	-2.83	
		5	#20 2.50 Sep35	0.66	-1.20	Oct05	5	#32 2.30 Mar40	2.52	-2.82	
		5	#34 2.20 Mar41	2.77	0.41	Mar11	5	#14 2.40 Mar34	0.87	-1.98	
		4	#9 1.40 Dec32	0.32	0.65	Jan03	4	#12 2.10 Sep33	0.52	-1.97	
		3	#36 2.00 Mar42	0.79	0.66	Mar12	3	#10 1.10 Mar33	0.53	-1.58	
		2	#37 1.90 Sep42 (30y)	0.75	0.78	Sep12	2	#11 1.70 Jun33	0.58	-1.55	
		1	#24 2.50 Sep36	0.61	1.09	Oct06	1	#9 1.40 Dec32	0.32	-1.40	

ZScore calculated using 6M history

2y,5y,7y,10y,20y,30y denote the OTR bonds

Analysis as of 5-Dec-12


Source: Citi Research

Figure 38. 6M carry in JPY swaps⁴

fwd/tenor	1Y	2Y	3Y	4Y	5Y	6Y	7Y	8Y	9Y	10Y	12Y	15Y	20Y	25Y	30Y	40Y
SPOT	- 9.0	- 3.2	- 1.6	- 0.1	1.6	3.3	5.1	6.2	7.2	7.7	8.4	8.0	6.0	4.5	3.8	3.2
6M	- 4.6	- 2.5	- 0.8	0.7	2.4	4.2	5.7	6.7	7.4	7.9	8.3	7.8	5.8	4.4	3.8	3.2
9M	- 5.9	- 3.1	- 1.0	0.9	2.8	4.7	6.0	7.1	7.8	8.3	8.6	8.0	5.8	4.4	3.9	3.2
1Y	- 0.4	0.3	1.4	3.0	4.7	6.3	7.4	8.3	8.8	9.2	9.2	8.4	6.1	4.7	4.1	3.5
2Y	1.0	2.3	4.0	5.8	7.5	8.7	9.4	9.8	10.1	10.1	9.8	8.5	6.0	4.8	4.2	3.5
3Y	3.6	5.5	7.4	9.2	10.2	10.9	11.1	11.3	11.2	11.0	10.2	8.6	6.0	4.9	4.4	3.6
4Y	7.6	9.4	11.2	12.0	12.4	12.5	12.5	12.4	12.0	11.5	10.4	8.4	6.0	4.9	4.4	3.7
5Y	11.3	13.0	13.5	13.7	13.6	13.4	13.2	12.6	12.1	11.4	10.0	7.9	5.6	4.7	4.2	3.5
6Y	14.7	14.6	14.6	14.2	14.0	13.6	12.9	12.2	11.5	10.8	9.3	7.1	5.1	4.3	3.9	3.3
7Y	14.9	14.8	14.3	14.1	13.5	12.8	12.1	11.3	10.6	9.7	8.0	6.0	4.4	3.8	3.4	2.8
8Y	14.4	13.8	13.5	13.0	12.3	11.5	10.7	9.8	9.0	8.1	6.5	4.8	3.6	3.1	2.8	2.3
9Y	13.2	13.1	12.7	11.8	11.0	10.1	9.2	8.3	7.5	6.6	5.1	3.7	2.8	2.5	2.2	1.8
10Y	13.0	12.4	11.4	10.4	9.5	8.5	7.6	6.7	5.8	5.0	3.7	2.7	2.0	1.8	1.6	1.4
12Y	9.5	8.6	7.6	6.6	5.6	4.7	3.8	3.0	2.3	1.7	1.1	0.7	0.6	0.6	0.5	0.4
15Y	3.4	2.5	1.5	0.7	- 0.1	- 0.7	- 1.1	- 1.3	- 1.5	- 1.5	- 1.4	- 1.1	- 0.8	- 0.6	- 0.6	- 0.5
20Y	- 4.0	- 3.9	- 3.6	- 3.4	- 3.1	- 2.8	- 2.5	- 2.2	- 2.0	- 1.8	- 1.4	- 1.1	- 0.8	- 0.7	- 0.6	- 0.5
25Y	- 1.2	- 1.0	- 0.7	- 0.5	- 0.3	- 0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
30Y	0.8	0.8	0.7	0.7	0.6	0.5	0.5	0.5	0.4	0.4	0.3	0.3	0.2	0.2	0.2	0.1

Source: Citi Research

Figure 39. 6M carry profile of JGB⁵



Source: Citi Research

Figure 40. 6M carry table of JGB

JGB	Carry	Rolldown	Total
1y	-2.9	-3.0	-5.9
2y	-0.4	2.1	1.7
3y	1.7	5.6	7.4
4y	3.2	7.1	10.3
5y	4.1	7.5	11.6
6y	4.9	8.1	12.9
7y	5.4	8.5	13.9
8y	5.9	8.8	14.7
9y	6.3	8.1	14.3
10y	6.4	6.7	13.1
20y	5.9	1.8	7.8
30y	4.9	0.4	5.3

Source: Citi Research

⁴ Sectors with carry more than 5bp is highlighted in green while the carry less than 5bp is highlighted in red.

⁵ JGB carry profile and table is calculated from the relative value curve and it may vary from individual bonds given the repo rate.

Appendix A-1

Analyst Certification

The research analyst(s) primarily responsible for the preparation and content of this research report are named in bold text in the author block at the front of the product except for those sections where an analyst's name appears in bold alongside content which is attributable to that analyst. Each of these analyst(s) certify, with respect to the section(s) of the report for which they are responsible, that the views expressed therein accurately reflect their personal views about each issuer and security referenced and were prepared in an independent manner, including with respect to Citigroup Global Markets Inc and its affiliates. No part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) expressed by that research analyst in this report.

IMPORTANT DISCLOSURES

Analysts' compensation is determined based upon activities and services intended to benefit the investor clients of Citigroup Global Markets Inc. and its affiliates ("the Firm"). Like all Firm employees, analysts receive compensation that is impacted by overall firm profitability which includes investment banking revenues.

For important disclosures (including copies of historical disclosures) regarding the companies that are the subject of this Citi Research product ("the Product"), please contact Citi Research, 388 Greenwich Street, 28th Floor, New York, NY, 10013, Attention: Legal/Compliance [E6WYB6412478]. In addition, the same important disclosures, with the exception of the Valuation and Risk assessments and historical disclosures, are contained on the Firm's disclosure website at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures. Valuation and Risk assessments can be found in the text of the most recent research note/report regarding the subject company. Historical disclosures (for up to the past three years) will be provided upon request.

Guide to Citi Research High Yield Ratings: Coverage in the Citi Research High Yield universe is assigned a relative return based rating. Depending on the issuer under analysis ratings may be applied to either some or all of the issuer's debt securities, bank loans or other instruments. These ratings and their definitions are:

Guide to Citi Research High Yield Issue Ratings:

Buy (1): The analyst expects the six-month total return of the rated debt security or instrument to exceed the market value weighted average total return for the analyst's sector or comparable sub-index of the Citi High Yield Market Index

Neutral (2): The analyst expects the six-month total return of the rated debt security or instrument to be in line with the market value weighted average total return for the analyst's sector or comparable sub-index of the Citi High Yield Market Index

Sell (3): The analyst expects the six-month total return of the rated debt security or instrument to be below the market value weighted average total return for the analyst's sector or comparable sub-index of the Citi High Yield Market Index

Guide to Citi Research High Yield Sector/Issuer Portfolio Weightings:

Overweight: Over the next six months, the recommended sector or issuer is expected to outperform the returns on the relevant index or benchmark based on valuation and methodology provided below;

Marketweight: Over the next six months, the recommended sector or issuer is expected to perform in line with the returns on the relevant index or benchmark based on valuation and methodology provided below;

Underweight - Over the next six months, the recommended sector or issuer is expected to underperform the returns on the relevant index or benchmark based on valuation and methodology provided below;

Under Review: Citi Research has suspended the investment rating for this issuer because there is not a sufficient fundamental basis for determining an investment rating. The previous investment rating is no longer in effect for this issuer and should not be relied upon. To satisfy regulatory requirements, we correspond 'under review' to Hold in our ratings distribution table. However, we reiterate that we do not consider 'under review' to be a recommendation. For purposes of complying with ratings-distribution-disclosure rules, a Citi Research High Yield rating of Overweight is considered to correspond to a Buy recommendation; Marketweight and Neutral to a Hold recommendation; and Underweight to a Sell recommendation.

Valuation and Methodology: In Citi's High Yield Credit Research we assign a rating (Buy, Neutral or Sell) that, depending on the company under analysis, may be assigned to some or all of the company's debt securities. The rating is based on our credit view of the issuer and the relative value of its securities, taking into account the ratings assigned to the issuer by credit rating agencies and the market prices for the issuer's securities. Our credit view of an issuer is based upon our opinion as to whether the issuer will be able to service its debt obligations when they become due and payable. We may assess this by analyzing, among other things, the issuer's credit position using standard credit ratios such as cash flow to debt and fixed charge coverage (including and excluding capital investment). We also analyze the issuer's ability to generate cash flow by reviewing standard operational measures for comparable companies in the sector, such as revenue and earnings growth rates, margins, and the composition of the issuer's balance sheet relative to the operational leverage in its business.

NON-US RESEARCH ANALYST DISCLOSURES

Non-US research analysts who have prepared this report (i.e., all research analysts listed below other than those identified as employed by Citigroup Global Markets Inc.) are not registered/qualified as research analysts with FINRA. Such research analysts may not be associated persons of the member organization and therefore may not be subject to the NYSE Rule 472 and NASD Rule 2711 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account. The legal entities employing the authors of this report are listed below:

Citicorp Pty Ltd

Steven Mansell; Carl Ang

Citigroup Global Markets Japan Inc.

Maki Shimizu

OTHER DISCLOSURES

For securities recommended in the Product in which the Firm is not a market maker, the Firm is a liquidity provider in the issuers' financial instruments and may act as principal in connection with such transactions. The Firm is a regular issuer of traded financial instruments linked to securities that may have been recommended in the Product. The Firm regularly trades in the securities of the issuer(s) discussed in the Product. The Firm may engage in securities

transactions in a manner inconsistent with the Product and, with respect to securities covered by the Product, will buy or sell from customers on a principal basis.

Securities recommended, offered, or sold by the Firm: (i) are not insured by the Federal Deposit Insurance Corporation; (ii) are not deposits or other obligations of any insured depository institution (including Citibank); and (iii) are subject to investment risks, including the possible loss of the principal amount invested. Although information has been obtained from and is based upon sources that the Firm believes to be reliable, we do not guarantee its accuracy and it may be incomplete and condensed. Note, however, that the Firm has taken all reasonable steps to determine the accuracy and completeness of the disclosures made in the Important Disclosures section of the Product. The Firm's research department has received assistance from the subject company(ies) referred to in this Product including, but not limited to, discussions with management of the subject company(ies). Firm policy prohibits research analysts from sending draft research to subject companies. However, it should be presumed that the author of the Product has had discussions with the subject company to ensure factual accuracy prior to publication. All opinions, projections and estimates constitute the judgment of the author as of the date of the Product and these, plus any other information contained in the Product, are subject to change without notice. Prices and availability of financial instruments also are subject to change without notice. Notwithstanding other departments within the Firm advising the companies discussed in this Product, information obtained in such role is not used in the preparation of the Product. Although Citi Research does not set a predetermined frequency for publication, if the Product is a fundamental research report, it is the intention of Citi Research to provide research coverage of the/those issuer(s) mentioned therein, including in response to news affecting this issuer, subject to applicable quiet periods and capacity constraints. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in the Product must take into account existing public information on such security or any registered prospectus.

Investing in non-U.S. securities, including ADRs, may entail certain risks. The securities of non-U.S. issuers may not be registered with, nor be subject to the reporting requirements of the U.S. Securities and Exchange Commission. There may be limited information available on foreign securities. Foreign companies are generally not subject to uniform audit and reporting standards, practices and requirements comparable to those in the U.S. Securities of some foreign companies may be less liquid and their prices more volatile than securities of comparable U.S. companies. In addition, exchange rate movements may have an adverse effect on the value of an investment in a foreign stock and its corresponding dividend payment for U.S. investors. Net dividends to ADR investors are estimated, using withholding tax rates conventions, deemed accurate, but investors are urged to consult their tax advisor for exact dividend computations. Investors who have received the Product from the Firm may be prohibited in certain states or other jurisdictions from purchasing securities mentioned in the Product from the Firm. Please ask your Financial Consultant for additional details. Citigroup Global Markets Inc. takes responsibility for the Product in the United States. Any orders by US investors resulting from the information contained in the Product may be placed only through Citigroup Global Markets Inc.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers: Morgan Stanley & Co. LLC (Morgan Stanley) research reports may be available about the companies that are the subject of this Citi Research research report. Ask your Financial Advisor or use smithbarney.com to view any available Morgan Stanley research reports in addition to Citi Research research reports.

Important disclosure regarding the relationship between the companies that are the subject of this Citi Research research report and Morgan Stanley Smith Barney LLC and its affiliates are available at the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

This Citi Research research report has been reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval was conducted by the same person who reviewed this research report on behalf of Citi Research. This could create a conflict of interest.

The Citigroup legal entity that takes responsibility for the production of the Product is the legal entity which the first named author is employed by. The Product is made available in **Australia** through Citi Global Markets Australia Pty Ltd. (ABN 64 003 114 832 and AFSL No. 240992), participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in Australia to Private Banking wholesale clients through Citigroup Pty Limited (ABN 88 004 325 080 and AFSL 238098). Citigroup Pty Limited provides all financial product advice to Australian Private Banking wholesale clients through bankers and relationship managers. If there is any doubt about the suitability of investments held in Citigroup Private Bank accounts, investors should contact the Citigroup Private Bank in Australia. Citigroup companies may compensate affiliates and their representatives for providing products and services to clients. The Product is made available in **Brazil** by Citigroup Global Markets Brasil - CCTVM SA, which is regulated by CVM - Comissão de Valores Mobiliários, BACEN - Brazilian Central Bank, APIMEC - Associação dos Analistas e Profissionais de Investimento do Mercado de Capitais and ANBID - Associação Nacional dos Bancos de Investimento. Av. Paulista, 1111 - 11º andar - CEP. 01311920 - São Paulo - SP. If the Product is being made available in certain provinces of **Canada** by Citigroup Global Markets (Canada) Inc. ("CGM Canada"), CGM Canada has approved the Product. Citigroup Place, 123 Front Street West, Suite 1100, Toronto, Ontario M5J 2M3. This product is available in **Chile** through Banchile Corredores de Bolsa S.A., an indirect subsidiary of Citigroup Inc., which is regulated by the Superintendencia de Valores y Seguros. Agustinas 975, piso 2, Santiago, Chile. The Product is made available in **France** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 1-5 Rue Paul Cézanne, 8ème, Paris, France. The Product is distributed in **Germany** by Citigroup Global Markets Deutschland AG ("CGMD"), which is regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin). CGMD, Reuterweg 16, 60323 Frankfurt am Main. Research which relates to "securities" (as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)) is issued in **Hong Kong** by, or on behalf of, Citigroup Global Markets Asia Limited which takes full responsibility for its content. Citigroup Global Markets Asia Ltd. is regulated by Hong Kong Securities and Futures Commission. If the Research is made available through Citibank, N.A., Hong Kong Branch, for its clients in Citi Private Bank, it is made available by Citibank N.A., Citibank Tower, Citibank Plaza, 3 Garden Road, Hong Kong. Citibank N.A. is regulated by the Hong Kong Monetary Authority. Please contact your Private Banker in Citibank N.A., Hong Kong, Branch if you have any queries on or any matters arising from or in connection with this document. The Product is made available in **India** by Citigroup Global Markets India Private Limited, which is regulated by Securities and Exchange Board of India. Bakhtawar, Nariman Point, Mumbai 400-021. The Product is made available in **Indonesia** through PT Citigroup Securities Indonesia. 5/F, Citibank Tower, Bapindo Plaza, Jl. Jend. Sudirman Kav. 54-55, Jakarta 12190. Neither this Product nor any copy hereof may be distributed in Indonesia or to any Indonesian citizens wherever they are domiciled or to Indonesian residents except in compliance with applicable capital market laws and regulations. This Product is not an offer of securities in Indonesia. The securities referred to in this Product have not been registered with the Capital Market and Financial Institutions Supervisory Agency (BAPEPAM-LK) pursuant to relevant capital market laws and regulations,

and may not be offered or sold within the territory of the Republic of Indonesia or to Indonesian citizens through a public offering or in circumstances which constitute an offer within the meaning of the Indonesian capital market laws and regulations. The Product is made available in **Israel** through Citibank NA, regulated by the Bank of Israel and the Israeli Securities Authority. Citibank, N.A. Platinum Building, 21 Ha'arba'ah St, Tel Aviv, Israel. The Product is made available in **Italy** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. Via dei Mercanti, 12, Milan, 20121, Italy. The Product is made available in **Japan** by Citigroup Global Markets Japan Inc. ("CGMJ"), which is regulated by Financial Services Agency, Securities and Exchange Surveillance Commission, Japan Securities Dealers Association, Tokyo Stock Exchange and Osaka Securities Exchange. Shin-Marunouchi Building, 1-5-1 Marunouchi, Chiyoda-ku, Tokyo 100-6520 Japan. If the Product was distributed by SMBC Nikko Securities Inc. it is being so distributed under license. In the event that an error is found in an CGMJ research report, a revised version will be posted on the Firm's Citi Velocity website. If you have questions regarding Citi Velocity, please call (81 3) 6270-3019 for help. The Product is made available in **Korea** by Citigroup Global Markets Korea Securities Ltd., which is regulated by the Financial Services Commission, the Financial Supervisory Service and the Korea Financial Investment Association (KOFIA). Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. KOFIA makes available registration information of research analysts on its website. Please visit the following website if you wish to find KOFIA registration information on research analysts of Citigroup Global Markets Korea Securities Ltd. <http://dis.kofia.or.kr/fs/dis2/fundMgr/DISFundMgrAnalystPop.jsp?companyCd2=A03030&pageDiv=02>. The Product is made available in Korea by Citibank Korea Inc., which is regulated by the Financial Services Commission and the Financial Supervisory Service. Address is Citibank Building, 39 Da-dong, Jung-gu, Seoul 100-180, Korea. The Product is made available in **Malaysia** by Citigroup Global Markets Malaysia Sdn Bhd (Company No. 460819-D) ("CGMM") to its clients and CGMM takes responsibility for its contents. CGMM is regulated by the Securities Commission of Malaysia. Please contact CGMM at Level 43 Menara Citibank, 165 Jalan Ampang, 50450 Kuala Lumpur, Malaysia in respect of any matters arising from, or in connection with, the Product. The Product is made available in **Mexico** by Acciones y Valores Banamex, S.A. De C. V., Casa de Bolsa, Integrante del Grupo Financiero Banamex ("Accival") which is a wholly owned subsidiary of Citigroup Inc. and is regulated by Comision Nacional Bancaria y de Valores. Reforma 398, Col. Juarez, 06600 Mexico, D.F. In **New Zealand** the Product is made available to 'wholesale clients' only as defined by s5C(1) of the Financial Advisers Act 2008 ('FAA') through Citigroup Global Markets Australia Pty Ltd (ABN 64 003 114 832 and AFSL No. 240992), an overseas financial adviser as defined by the FAA, participant of the ASX Group and regulated by the Australian Securities & Investments Commission. Citigroup Centre, 2 Park Street, Sydney, NSW 2000. The Product is made available in **Pakistan** by Citibank N.A. Pakistan branch, which is regulated by the State Bank of Pakistan and Securities Exchange Commission, Pakistan. AWT Plaza, 1.1. Chundrigar Road, P.O. Box 4889, Karachi-74200. The Product is made available in the **Philippines** through Citicorp Financial Services and Insurance Brokerage Philippines, Inc., which is regulated by the Philippines Securities and Exchange Commission. 20th Floor Citibank Square Bldg. The Product is made available in the Philippines through Citibank NA Philippines branch, Citibank Tower, 8741 Paseo De Roxas, Makati City, Manila. Citibank NA Philippines NA is regulated by The Bangko Sentral ng Pilipinas. The Product is made available in **Poland** by Dom Maklerski Banku Handlowego SA an indirect subsidiary of Citigroup Inc., which is regulated by Komisja Nadzoru Finansowego. Dom Maklerski Banku Handlowego S.A. ul.Senatorska 16, 00-923 Warszawa. The Product is made available in the **Russian Federation** through ZAO Citibank, which is licensed to carry out banking activities in the Russian Federation in accordance with the general banking license issued by the Central Bank of the Russian Federation and brokerage activities in accordance with the license issued by the Federal Service for Financial Markets. Neither the Product nor any information contained in the Product shall be considered as advertising the securities mentioned in this report within the territory of the Russian Federation or outside the Russian Federation. The Product does not constitute an appraisal within the meaning of the Federal Law of the Russian Federation of 29 July 1998 No. 135-FZ (as amended) On Appraisal Activities in the Russian Federation. 8-10 Gasheka Street, 125047 Moscow. The Product is made available in **Singapore** through Citigroup Global Markets Singapore Pte. Ltd. ("CGMSPL"), a capital markets services license holder, and regulated by Monetary Authority of Singapore. Please contact CGMSPL at 8 Marina View, 21st Floor Asia Square Tower 1, Singapore 018960, in respect of any matters arising from, or in connection with, the analysis of this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). The Product is made available by The Citigroup Private Bank in Singapore through Citibank, N.A., Singapore Branch, a licensed bank in Singapore that is regulated by Monetary Authority of Singapore. Please contact your Private Banker in Citibank N.A., Singapore Branch if you have any queries on or any matters arising from or in connection with this document. This report is intended for recipients who are accredited, expert and institutional investors as defined under the Securities and Futures Act (Cap. 289). This report is distributed in Singapore by Citibank Singapore Ltd ("CSL") to selected Citigold/Citigold Private Clients. CSL provides no independent research or analysis of the substance or in preparation of this report. Please contact your Citigold/Citigold Private Client Relationship Manager in CSL if you have any queries on or any matters arising from or in connection with this report. This report is intended for recipients who are accredited investors as defined under the Securities and Futures Act (Cap. 289). Citigroup Global Markets (Pty) Ltd. is incorporated in the **Republic of South Africa** (company registration number 2000/025866/07) and its registered office is at 145 West Street, Sandton, 2196, Saxonwold. Citigroup Global Markets (Pty) Ltd. is regulated by JSE Securities Exchange South Africa, South African Reserve Bank and the Financial Services Board. The investments and services contained herein are not available to private customers in South Africa. The Product is made available in **Spain** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. 29 Jose Ortega Y Gasset, 4th Floor, Madrid, 28006, Spain. The Product is made available in the **Republic of China** through Citigroup Global Markets Taiwan Securities Company Ltd. ("CGMTS"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan and/or through Citibank Securities (Taiwan) Company Limited ("CSTL"), 14 and 15F, No. 1, Songzhi Road, Taipei 110, Taiwan, subject to the respective license scope of each entity and the applicable laws and regulations in the Republic of China. CGMTS and CSTL are both regulated by the Securities and Futures Bureau of the Financial Supervisory Commission of Taiwan, the Republic of China. No portion of the Product may be reproduced or quoted in the Republic of China by the press or any third parties [without the written authorization of CGMTS and CSTL]. If the Product covers securities which are not allowed to be offered or traded in the Republic of China, neither the Product nor any information contained in the Product shall be considered as advertising the securities or making recommendation of the securities in the Republic of China. The Product is for informational purposes only and is not intended as an offer or solicitation for the purchase or sale of a security or financial products. Any decision to purchase securities or financial products mentioned in the Product must take into account existing public information on such security or the financial products or any registered prospectus. The Product is made available in **Thailand** through Citicorp Securities (Thailand) Ltd., which is regulated by the Securities and Exchange Commission of Thailand. 18/F, 22/F and 29/F, 82 North Sathorn Road, Silom, Bangrak, Bangkok 10500, Thailand. The Product is made available in **Turkey** through Citibank AS which is regulated by Capital Markets Board. Tekfen Tower, Eski Buyukdere Caddesi # 209 Kat 2B, 23294 Levent, Istanbul, Turkey. In the **U.A.E.** these materials (the "Materials") are communicated by Citigroup Global Markets Limited, DIFC branch ("CGML"), an entity registered in the Dubai International Financial Center ("DIFC") and licensed and regulated by the Dubai Financial Services Authority ("DFSA") to Professional Clients and Market Counterparties only and should not be relied upon or distributed to Retail Clients. A distribution of the different Citi Research ratings distribution, in percentage terms for Investments in each sector covered is made available on

request. Financial products and/or services to which the Materials relate will only be made available to Professional Clients and Market Counterparties. The Product is made available in **United Kingdom** by Citigroup Global Markets Limited, which is authorised and regulated by Financial Services Authority. This material may relate to investments or services of a person outside of the UK or to other matters which are not regulated by the FSA and further details as to where this may be the case are available upon request in respect of this material. Citigroup Centre, Canada Square, Canary Wharf, London, E14 5LB. The Product is made available in **United States** by Citigroup Global Markets Inc, which is a member of FINRA and registered with the US Securities and Exchange Commission. 388 Greenwich Street, New York, NY 10013. Unless specified to the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Limited, which is regulated by Financial Services Authority.

Pursuant to Comissão de Valores Mobiliários Rule 483, Citi is required to disclose whether a Citi related company or business has a commercial relationship with the subject company. Considering that Citi operates multiple businesses in more than 100 countries around the world, it is likely that Citi has a commercial relationship with the subject company.

Many European regulators require that a firm must establish, implement and make available a policy for managing conflicts of interest arising as a result of publication or distribution of investment research. The policy applicable to Citi Research's Products can be found at https://www.citivelocity.com/cvr/eppublic/citi_research_disclosures.

Compensation of equity research analysts is determined by equity research management and Citigroup's senior management and is not linked to specific transactions or recommendations.

The Product may have been distributed simultaneously, in multiple formats, to the Firm's worldwide institutional and retail customers. The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to sudden and large falls in value that could equal or exceed the amount invested. Certain investments contained in the Product may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt, investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Accordingly, investors should, before acting on the advice, consider the appropriateness of the advice, having regard to their objectives, financial situation and needs. Prior to acquiring any financial product, it is the client's responsibility to obtain the relevant offer document for the product and consider it before making a decision as to whether to purchase the product. With the exception of our product that is made available only to Qualified Institutional Buyers (QIBs) and other product that is made available through other distribution channels only to certain categories of clients to satisfy legal or regulatory requirements, Citi Research concurrently disseminates its research via proprietary and non-proprietary electronic distribution platforms. Periodically, individual Citi Research analysts may also opt to circulate research posted on such platforms to one or more clients by email. Such email distribution is discretionary and is done only after the research has been disseminated via the aforementioned distribution channels. Citi Research simultaneously distributes product that is limited to QIBs only through email distribution.

The level and types of services provided by Citi Research analysts to clients may vary depending on various factors such as the client's individual preferences as to the frequency and manner of receiving communications from analysts, the client's risk profile and investment focus and perspective (e.g. market-wide, sector specific, long term, short-term etc.), the size and scope of the overall client relationship with Citi and legal and regulatory constraints. Citi Research product may source data from dataCentral. dataCentral is a Citi Research proprietary database, which includes Citi estimates, data from company reports and feeds from Reuters and Datastream.

© 2012 Citigroup Global Markets Inc. Citi Research is a division of Citigroup Global Markets Inc. Citi and Citi with Arc Design are trademarks and service marks of Citigroup Inc. and its affiliates and are used and registered throughout the world. All rights reserved. Any unauthorized use, duplication, redistribution or disclosure of this report (the "Product"), including, but not limited to, redistribution of the Product by electronic mail, posting of the Product on a website or page, and/or providing to a third party a link to the Product, is prohibited by law and will result in prosecution. The information contained in the Product is intended solely for the recipient and may not be further distributed by the recipient to any third party. Where included in this report, MSCI sourced information is the exclusive property of Morgan Stanley Capital International Inc. (MSCI). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, redisseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI, Morgan Stanley Capital International and the MSCI indexes are services marks of MSCI and its affiliates. The Firm accepts no liability whatsoever for the actions of third parties. The Product may provide the addresses of, or contain hyperlinks to, websites. Except to the extent to which the Product refers to website material of the Firm, the Firm has not reviewed the linked site. Equally, except to the extent to which the Product refers to website material of the Firm, the Firm takes no responsibility for, and makes no representations or warranties whatsoever as to, the data and information contained therein. Such address or hyperlink (including addresses or hyperlinks to website material of the Firm) is provided solely for your convenience and information and the content of the linked site does not in anyway form part of this document. Accessing such website or following such link through the Product or the website of the Firm shall be at your own risk and the Firm shall have no liability arising out of, or in connection with, any such referenced website.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST